1161 - Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with metastatic non-small cell lung cancer

Page last updated: 13 July 2016

Application Detail

Status

Closed

Description of Medical Service

This application seeks to extend availability of a test already funded on the MBS for use of gefitinib for first-line treatment in patients with locally advanced or metastatic NSCLC.

Description of Medical Condition

There are three histological defined subgroups of NSCLC: (i) adenocarcinoma – often found in an outer area of the lung; (ii) squamous cell carcinoma – usually found in the centre of the lung by an air tube (bronchus); and (iii) large cell carcinoma – may occur in any part of the lung which tends to grow and spread faster than the other two types.

Regardless of the subgroup, NSCLC arises as a consequence of either acquired (somatic) and/or inherited (germ-line) mutations.

Reason for Application

-

Medical Service Type

-

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

Final Decision Analytic Protocol (DAP) (PDF 394 KB)
Final Decision Analytic Protocol (DAP) (Word 747 KB)

Assessment Report

Public Summary Document - November 2012 (PDF 927 KB)
Public Summary Document - November 2012 (Word 329 KB)

Public Summary Document - August 2013 (PDF 129 KB)
Public Summary Document - August 2013 (Word 99 KB)

Public Summary Document

-

Meetings for this Application

PASC

7 July 2011
14 - 15 September 2011

ESC

11 - 12 October 2012

MSAC

29 - 30 November 2012
1 August 2013